EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders

Jun Han Kuan, Roshan S Raghavan, Dawn Li Wei Koh, Wing Yeng Tan iD, Igor Iezhitsa iD, Renu Agarwal iD

Neuroprotection · 2026-03 · 4 (1) · 30-47

DOI: 10.1002/nep3.70026 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuroprotection, online erschienen am 17.02.2026. Verfasst von Jun Han Kuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Pharmacology, School of Medicine IMU University Kuala Lumpur Malaysia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: International Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases such as Alzheimer's (AD), Parkinson's (PD), Huntington's (HD), and multiple sclerosis (MS) involve progressive neuronal loss driven by dysregulated neurotransmission, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Cholesterol metabolism has emerged as a critical factor involved with both central and peripheral dysregulation contributing to pathology. This review synthesizes current evidence on cholesterol's role in neurodegeneration and evaluates the therapeutic potential of statins, which act via cholesterol‐dependent and other pleiotropic mechanisms. A PubMed search covering 1985–2025 publications was conducted using terms related to neurodegenerative diseases, statins, cholesterol metabolism, neuroinflammation, oxidative stress, mitochondrial dysfunction, and neuroprotection. Studies were selected to highlight mechanistic insights into cholesterol regulation in the nervous system and clinical data on statin use. Neuronal loss in neurodegeneration is driven by processes including excitotoxicity, inflammation, and mitochondrial dysfunction. Excessive reactive oxygen species activate apoptotic pathways involving BAX , BAK , and p53 . Dysregulated cholesterol metabolism is a significant contributor: In AD, the ApoE allele ε4 ( ApoE4 ) links elevated cholesterol to amyloid‐β (Aβ) accumulation and cognitive decline; in PD, cholesterol shows mixed effects, with some studies suggesting protection and others linking high levels to α‐synuclein aggregation and mitochondrial impairment. In HD reduced cholesterol biosynthesis correlates with neuronal loss, while MS associates with elevated cholesterol and cognitive dysfunction. Statins, widely used cholesterol‐lowering agents, reduce Aβ production, enhance its clearance, and improve synaptic function. Beyond lipid lowering, they exert anti‐inflammatory, antioxidant, and anti‐apoptotic effects. Clinical outcomes remain mixed, with benefits influenced by statin type, dose, treatment duration, disease stage, and patient genetics. Statins show multifaceted neuroprotective potential through cholesterol‐dependent and independent pathways. While preclinical data are encouraging, clinical evidence is heterogeneous. Long‐term, stratified trials are needed to clarify efficacy, and tailoring therapy to disease‐specific mechanisms may offer a viable strategy for mitigating neurodegeneration and enhancing neuronal survival.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseHuntington's diseaseParkinson's diseasecholesterol/metabolismhydroxymethylglutaryl‐CoA reductase inhibitorsmultiple sclerosisneurodegenerative diseasesneuroinflammationneuroprotectionoxidative stress

Autor:innen und Institutionen

  • Department of Pathology and Pharmacology, School of Medicine IMU University Kuala Lumpur Malaysia.
  • Ninewells Hospital and Medical School School of Medicine, University of Dundee Dundee Scotland UK.
  • School of Undergraduate Medicine University of Glasgow Glasgow Scotland UK.

ORCID-Profile: Wing Yeng Tan, Igor Iezhitsa, Renu Agarwal

Förderung

  • International Medical University

Zitieren

APA

Kuan, J. H., Raghavan, R. S., Koh, D. L. W., Tan, W. Y., Iezhitsa, I., & Agarwal, R. (2026). Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection, 4(1), 30-47. https://doi.org/10.1002/nep3.70026

Vancouver

Kuan JH, Raghavan RS, Koh DLW, Tan WY, Iezhitsa I, Agarwal R. Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection. 2026;4(1):30-47. doi:10.1002/nep3.70026

BibTeX
@article{Kuan2026,
  author = {Kuan, Jun Han and Raghavan, Roshan S and Koh, Dawn Li Wei and Tan, Wing Yeng and Iezhitsa, Igor and Agarwal, Renu},
  title = {Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders},
  journal = {Neuroprotection},
  year = {2026},
  volume = {4},
  number = {1},
  pages = {30--47},
  doi = {10.1002/nep3.70026}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche